Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

Company Also Provides Update on DARA Program's Ongoing Phase 2a

Hypertension Study

PRINCETON, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the nomination of PS031291 as a preclinical development compound from its internal CCR1 discovery program. PS031291 is a potent and highly selective antagonist at the chemokine receptor CCR1, which has been implicated to play a significant role in multiple inflammatory and autoimmune disease processes. Pharmacopeia believes PS031291 may possess significant potential in the oral treatment of multiple myeloma and various inflammatory diseases including rheumatoid arthritis. The company intends to initiate GLP toxicology studies on the compound in the current quarter.

"PS031291 strengthens Pharmacopeia's internal pipeline with a wholly-owned development candidate with the potential to address significant therapeutic needs," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We believe this nomination is a testament to our drug discovery expertise which has already generated a number of clinical compounds for our strategic partners."

While a number of compounds discovered by Pharmacopeia are being developed by its various collaborators, PS031291 is the first compound to emerge from Pharmacopeia's internal drug discovery efforts into its internal development portfolio. Pharmacopeia's internal clinical pipeline consists of PS433540 (DARA) for hypertension and diabetic nephropathy and PS178990 (SARM) for muscle wasting associated with a number of serious medical conditions including end-stage renal disease
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Texas , Oct. 1, 2014 ... is scaling volume production of photoactive quantum dots ... technologies . While offering numerous advantages for solar ... producing large quantities of quantum dots with which ... now kept them from commercial utilization and acceptance. ...
(Date:10/1/2014)... , Oct. 1, 2014 ... a clinical-stage biopharmaceutical company focused on cardio-renal, ... results from its 371 patient Phase 2b ... constipation-predominant irritable bowel syndrome (IBS-C).  Results from ... meaningful improvement in IBS-C symptoms for tenapanor-treated ...
(Date:10/1/2014)... Switzerland , October 1, 2014 /PRNewswire/ ... Clinical Genomics and Next Generation Sequencing (NGS) data analysis, ... to run full cystic fibrosis analysis in a single ... and characterisation of all types of variants in a ... Until now, it has not been possible to ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Predicting the future course of psychotic illness 2Health News:Eighty percent of bowel cancers halted with existing medicines 2
... citrus fruits rich in Vitamin C such as papaya, oranges ... research has found that the nutrient could help reduce ... ,Researchers from the University of Warwick have found that the ... in diabetics. ,Free radicals are tissue-damaging molecules, and ...
... and smoke-free work environment play key roles in helping people ... a study has found. ,The study was ... environmental factors are more influential than individual behaviours and beliefs ... researcher Jon Macy, said that though smoking cessation attempts often ...
... , ... ... ... clutches? Even fetuses in wombs experience stress! Stress can stem from a variety of causes-relationships, job, school and daily activities-just about anything. ...
... Working in an environment where smoking is allowed is especially ... that is not considered safe at any level, a ... by researchers at the Multnomah County Health Department and Oregon ... elevated levels of the carcinogen NNK, which is found in ...
... led by a Children's Hospital of Eastern Ontario (CHEO )researcher ... to vitamin D deficiency Rickets. Despite the fact that generation ... supplements and sunshine, vitamin D deficiency rickets has persisted in ... disease that weakens the leg bones and stunts growth, the ...
... death rates for men from the rural areas are 10 ... ,Despite The fact that cancer survival rates are improving overall, ... death rate of men living in rural areas and their ... in Australia has risen from 78,857 new cases in 1996 ...
Cached Medicine News:Health News:Smoke-free Workplace, Non-smoking Spouse Help Quitters Stay Off the Butt 2Health News:Living With Stress 2Health News:Living With Stress 3Health News:Living With Stress 4Health News:Secondhand Workplace Smoke Hits Non-smokers Badly 2Health News:Vitamin D Deficiency Still Persists in Babies 2Health News:Cancer Deaths of Rural Men on the High 2
... The Repeater Pipette* provides quick, convenient, ... procedures. Eppendorf Combitips have a polyethylene ... them ideal for use with most ... Product features: Five separate volumes can ...
... The only catheter of its kind, ... rapidly collects real-time cardiac electrical information, ... map. With 64 electrodes, this unique ... more than 3,000 points of electrical ...
... St. Jude Medical's universal programmer platform, ... used in combination with St. Jude ... products for emerging indications. Features ... touch-sensitive, active matrix LCD screen Programmer ...
... Coronary Stent System introduces ... lesion access and conformability. ... low crossing profile, and ... the performance of the ...
Medicine Products: